SRTA vs TMO
SRTA: A time-critical logistics and clinical services provider offering integrated air/ground organ transport, surgical organ recovery, and cardiac perfusion solutions to the U.S. transplant ecosystem. TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries.
Side-by-side fundamentals
| Metric | SRTA | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $5.09 | $572.32 | |
| Market cap as of 2026-07-24 | $437M | $214.1B | |
| P/E as of 2026-07-24 | 9.31 | 31.28 | SRTA lower |
| PEG as of 2026-07-24 | n/a | 2.89 | |
| Net margin as of 2026-07-24 | +18.5% | +15.2% | SRTA higher |
| Gross margin as of 2026-07-24 | -39.7% | +40.9% | TMO higher |
| Operating margin as of 2026-07-24 | -7.8% | +17.5% | TMO higher |
| ROE as of 2026-07-24 | +17.5% | +13.2% | SRTA higher |
| ROA as of 2026-07-24 | +15.1% | +6.4% | SRTA higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.83 | SRTA lower |
| Revenue growth (YoY) as of 2026-07-24 | +19.6% | +5.4% | SRTA higher |
| Revenue CAGR (3y) SEC XBRL | +10.5% | -0.3% | SRTA higher |
| Dividend yield as of 2026-07-24 | n/a | +0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 2.27 | 0.84 | |
| 1-year return as of 2026-07-23 close | +14.7% | +22.6% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.